A Phase 1, First-in-human Study of MORF-440 (LY4292009) in Healthy Participants

Inclusion Criteria10

• Body mass index (BMI) within 18.0 kg/m² to 30.0 kg/m², inclusive
• If male, meets one of the following:
• can procreate and agree to use one of the accepted to use one of the accepted contraceptive regimens and not to donate sperm from the first study drug administration to at least 90 days after the last drug administration.
• is unable to procreate; defined as surgically sterile (i.e., has undergone a vasectomy at least 180 days prior to the first study drug administration)
• if female, meets one of the following:
• is of childbearing potential and agrees to use an acceptable contraceptive method.
• is of non-childbearing potential, defined as either:
• Surgically sterile (i.e., has undergone complete hysterectomy, bilateral oophorectomy, or tubal ligation) or
• is in a postmenopausal state:
• At least 1 year without menses and without an alternative medical condition prior to the screening, and follicle stimulating hormone (FSH) levels ≥ 40 mIU/mL at screening or at least 1 year without menses and without an alternative medical condition prior to the screening, follicle stimulating hormone FSH levels < 40 milli-international units per milliliter (mIU/mL) and estradiol serum level ≤150 picomole/Liter (pmol/L) at screening